Natingor, Marylyne B.
HRN: 26-00-09 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/03/2024
MUPIROCIN 2%, 15G (TUBE)
10/03/2024
10/10/2024
TOPICAL
Apply On Affected Area
BID
Infected Breast Mass
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes